Intravenous Lidocaine: Old-School Drug, New Purpose-Reduction of Intractable Pain in Patients with Chemotherapy Induced Peripheral Neuropathy

Pain Res Manag. 2017:2017:8053474. doi: 10.1155/2017/8053474. Epub 2017 Mar 28.


Background. Treatment of intractable pain due to chemotherapy induced peripheral neuropathy (CIPN) is a challenge. Intravenous (iv) lidocaine has shown to be a treatment option for neuropathic pain of different etiologies. Methods. Lidocaine (1.5 mg/kg in 10 minutes followed by 1.5 mg/kg/h over 5 hours) was administered in nine patients with CIPN, and analgesic effect was evaluated during infusion and after discharge. The immediate effect of lidocaine on pressure pain thresholds (PPT) and the extent of the stocking and glove distribution of sensory abnormalities (cold and pinprick) were assessed. Results. Lidocaine had a significant direct analgesic effect in 8 out of 9 patients (P = 0.01) with a pain intensity difference of >30%. Pain reduction persisted in 5 patients for an average of 23 days. Lidocaine did not influence mean PPT, but there was a tendency that the extent of sensory abnormalities decreased after lidocaine. Conclusion. Iv lidocaine has direct analgesic effect in CIPN with a moderate long-term effect and seems to influence the area of cold and pinprick perception. Additional research is needed, using a control group and larger sample sizes to confirm these results.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Anesthetics, Local / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Cohort Studies
  • Female
  • Humans
  • Infusions, Intravenous
  • Lidocaine / administration & dosage*
  • Male
  • Middle Aged
  • Pain, Intractable / drug therapy*
  • Pain, Intractable / etiology
  • Peripheral Nervous System Diseases / drug therapy*
  • Peripheral Nervous System Diseases / etiology
  • Prospective Studies


  • Anesthetics, Local
  • Antineoplastic Agents
  • Lidocaine